Page 1

R REPLIGEN NEWS RELEASE Repligen Reports Third Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance 2021-10-28 • Reports record revenue of $ 178.2 million for the quarter , representing year - over - year growth of 89 % and organic growth of 77 % • Raises revenue guidance to $ 655- $ 665 million for full year 2021 • Completes acquisition of affinity ligands innovator Avitide Inc. WALTHAM , Mass . , Oct. 28 , 2021 ( GLOBE NEWSWIRE ) -- Repligen Corporation ( NASDAQ : RGEN ) , a life sciences company focused on bioprocessing technology leadership , today reported financial results for its third quarter of 2021. Provided in this press release are financial highlights for the three- and nine - month periods ended September 30 , 2021 , updates to our financial guidance for the fiscal year 2021 and access information for today's webcast and conference call . Tony J. Hunt , President and Chief Executive Officer said , " We delivered strong overall performance during the third quarter , with record revenue of $ 178 million and organic growth of 77 % year - over - year . Our base business delivered 49 % organic growth , reflecting an outstanding quarter across all franchises . COVID programs accounted for approximately 27 % of revenue during the third quarter , and gene therapy customer revenue grew more than 50 % year - over - year . Strategically , we strengthened and expanded our Proteins franchise through a series of new product introductions , a new long term supply agreement with Cytiva and our acquisition of Avitide . We are confident about the full year outlook for the company , including operating margin expansion , overall revenue growth of 79 % -82 % , and organic growth in the range of 65 % -68 % . " Financial Highlights for the Third Quarter 2021 1